Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies

Review

(2373) Views  (804) Full article downloads

Authors: Kem P Krueger, A Christie Nelson

Published Date August 2009 Volume 2009:1 Pages 35 - 43

DOI: http://dx.doi.org/10.2147/CEOR.S4244

Kem P Krueger, A Christie Nelson

School of Pharmacy, University of Wyoming, Laramie, WY, USA

Abstract: Invasive aspergillosis is a life-threatening fungal infection predominately affecting immunocompromised individuals. The incidence of inpatient-treated aspergillosis cases in the US is estimated to be between 3.02 and 3.80 per 10,000 hospitalized patients. The estimated difference in hospital costs of patients with an aspergillosis infection is US$36,867 to US$59,356 higher than those of patients without the infection. Voriconazole is a synthetic, broad spectrum triazole antifungal agent, with FDA-approved indications for the treatment of invasive aspergillosis, esophageal candidiasis, candidemia in nonneutropenic patients, invasive candidiasis, and infections due to Scedosporium apiospermum and Fusarium species in patients refractory to or intolerant of other therapy. Eight cost-effectiveness analyses, one cost-minimization analysis, and one cost analysis were identified from a Medline search. The 10 pharmacoeconomic analyses were conducted in six different countries comparing voriconazole to conventional amphotericin B, liposomal amphotericin B, itraconazole, and caspofungin. All the cost-effectiveness and cost-minimization analyses identified voriconazole as the most cost-effective therapy. The cost analysis demonstrated voriconazole cost-savings. While the acquisition costs of voriconazole are higher than those of conventional amphotericin B, the toxicity profile and rate of treatment success associated with voriconazole result in lower total treatment costs per successfully treated patient.

Keywords: voriconazole, antifungal agents, invasive aspergillosis, pharmacoeconomics